These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33115558)

  • 1. The 'Holy Grail' in Immuno-Oncology: AC BioScience SA is Aiming to Potentiate Anti-PD-1 Therapy Efficacy through Tumor Cell Conditioning Strategy.
    Schläpfer A; Auclair C; Janji B; Karam M; Zaeem Noman M
    Chimia (Aarau); 2020 Oct; 74(10):771-775. PubMed ID: 33115558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
    Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology.
    Rodallec A; Fanciullino R; Benzekry S; Ciccolini J;
    Anticancer Res; 2019 Jul; 39(7):3419-3422. PubMed ID: 31262864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Benefits of combining chemotherapy with immuno- oncology therapies or "Is it true that chemotherapy destroys the immune system?"].
    Kocsis J
    Magy Onkol; 2019 Sep; 63(3):202-207. PubMed ID: 31533140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy.
    Chowdhury PS; Chamoto K; Honjo T
    J Intern Med; 2018 Feb; 283(2):110-120. PubMed ID: 29071761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABI 007.
    Drugs R D; 2004; 5(3):155-9. PubMed ID: 15139776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
    Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
    Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New.
    Bangalore Kumar A; Maus R; Markovic SN
    Mayo Clin Proc; 2018 Jul; 93(7):917-936. PubMed ID: 29887221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
    Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S
    Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
    Lee HT; Lee SH; Heo YS
    Molecules; 2019 Mar; 24(6):. PubMed ID: 30917623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint inhibitors: a cutting edge in oncology.
    Jago C
    Drugs Today (Barc); 2017 Jul; 53(7):399-404. PubMed ID: 28837184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.
    Constantinidou A; Alifieris C; Trafalis DT
    Pharmacol Ther; 2019 Feb; 194():84-106. PubMed ID: 30268773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
    Adachi K; Tamada K
    Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy.
    Cho Y; Milane L; Amiji MM
    Expert Opin Biol Ther; 2019 Jun; 19(6):547-560. PubMed ID: 30933545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
    Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
    Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics.
    Hegde PS; Wallin JJ; Mancao C
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):117-124. PubMed ID: 29229461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selecting immuno-oncology-based drug combinations - what should we be considering?
    Festino L; Vanella V; Trojaniello C; Ascierto PA
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):971-985. PubMed ID: 30169990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.